Loading
companiesCompany
Sofinnova Partners
One of Europe's oldest life sciences venture firms, based in Paris. It has backed cancer companies such as Innate Pharma, Crescendo Biologics and Hookipa, and its portfolio company Myricx was bought by Novartis.
Overview
Sofinnova Partners states that it was 'Founded in 1972' and 'has backed more than 500 companies over 50 years', and that it 'has over EUR 4 billion under management' (homepage). It runs several strategies across the value chain: Sofinnova Capital (early-stage biopharma and medtech, often company creation), Crossover (later-stage), MD Start (medtech incubation), Industrial Biotech, Digital Medicine, Biovelocita (Italian accelerator) and a Telethon fund. Its portfolio page lists oncology companies including Innate Pharma (natural killer cell-directed antibodies), Crescendo Biologics (Humabody T-cell engagers), Hookipa Pharma (arenavirus immunotherapy), Inspirna and iOmx Therapeutics (immuno-oncology). The news page features 'the journey behind Myricx's acquisition by Novartis' (Myricx develops antibody-drug conjugate payloads).
Portfolio (1)
Filter the startups table| Company | Stage | Type | Cancers | Latest round |
|---|---|---|---|---|
| Mablink Bioscience Lyon, FR | Acquired | biotech | Acquisition 2023 |
Notes
top- Portfolio page lists company names and strategy tags but no descriptions; oncology focus of the named companies is from general knowledge. Paris headquarters follows the task hint; the fetched pages did not show an address.
Similar pages
- CompanyCytomX Therapeutics
Shares T-cell engagers (bispecific), Antibody-drug conjugate (ADC).
- IdeaFlush dormant cells out of bone marrow, then kill them
Shares T-cell engagers (bispecific), Antibody-drug conjugate (ADC).
- TrialA Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma
Shares T-cell engagers (bispecific), Antibody-drug conjugate (ADC).
- IdeaAn open engineering platform for academic ADCs and bispecifics
Shares T-cell engagers (bispecific), Antibody-drug conjugate (ADC).
- PersonElias Jabbour
Shares T-cell engagers (bispecific), Antibody-drug conjugate (ADC).
- TrialAn Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
Shares T-cell engagers (bispecific), Antibody-drug conjugate (ADC).
- TrialSafety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL)
Shares Novartis, T-cell engagers (bispecific).
- IdeaEfflux-agnostic therapy for mesenchymal TNBC
Shares T-cell engagers (bispecific), Antibody-drug conjugate (ADC).